| Revenue growth | 23% YoY for full year FY26. |
|---|---|
| Margins | Gross margin healthy at 60%; EBITDA reached 29% in Q4. |
| Order book | Pretty much in place for next year. |
| Demand visibility | Strong momentum in CDMO and non-ARV generics. |
| Management confidence | High; confident in maintaining or improving EBITDA margins in FY27. |
Growth
FY26 Revenue grew 23% to ₹6,813 Cr; PAT surged 148% to ₹889 Cr; EBITDA margins expanded 6.7% to 26.8%.
Outlook
Guided ₹3,000 Cr capex over next 2 years; CDMO targeted to be 50% of revenue by FY30.
Risks
Geopolitical disruptions affecting raw material availability/logistics; solvent price volatility; increased debt for capex.
Earnings Call filed with NSE, NSE: LAURUSLABS. Summary written with AI assistance from the document.
Laurus Labs Ltd: key numbers
- Share price
- ₹2,052.80
- Market cap
- ₹1,10,915 Cr
- Revenue (annual)
- ₹6,813 Cr
- Net profit (annual)
- ₹888.8 Cr
- P/E (TTM)
- 101.4×Sector 47.3×
- Promoter holding
- 27.47%-0.02% QoQ
- FII holding
- 28.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Laurus Labs Ltd
All →Laurus Labs Investor Presentation: Key Takeaways
Laurus Labs delivered record Q1FY27 revenue of ₹2,026 Cr, a 29% YoY increase, driven by robust CDMO growth. EBITDA margins expanded 700 bps YoY to 31.8% on favorable mix.
Laurus Labs Other Announcement
Laurus Labs has been assigned an ESG score of 63 out of 100 for FY 2026 by NSE Sustainability Ratings and Analytics Limited.
Laurus Labs Employee Stock Options
Laurus Labs has allotted 62,635 equity shares to employees upon the exercise of vested stock options under its ESOP schemes.
Laurus Labs Merger & Restructuring
Laurus Labs announced the NCLT has issued an order regarding its Composite Scheme of Arrangement. The court directed notices be served for the upcoming September hearing.
Laurus Labs Earnings Call Transcript: Key Takeaways
Laurus Labs delivered record quarterly revenue and EBITDA margins, driven by strong CDMO commercial supplies and recovery in the affordable medicine portfolio.
- Call
- Guides 50% growth
Laurus Labs Results Update
Laurus Labs reported Q1 FY27 revenue of ₹2,026 Crore and EBITDA of ₹644 Crore. The results show 29% year-on-year revenue growth.